Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the quarter-end Xenon position value decreased by $62.94 million, reflecting both trading and stock price movement.

Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Trading Up 2.0% Shares of XENE stock opened at $42.51 on Thursday.

The Dow tapped a third consecutive record high thanks to a bounce back in software stocks

Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors bought 4,063 put options on the company. This represents an increase of 2,362% compared to the average volume of 165 put options. Insider Activity at Xenon Pharmaceuticals In other Xenon Pharmaceuticals news, CEO Ian

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).

Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD)

VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company's Phase 3 portfolio and discussed pipeline progress at the 2026 J.P. Morgan Healthcare Conference.

VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.